Jump to content

Info @ Drug called Tarceva for BAC from Memorial Sloan Ket.


Melinda

Recommended Posts

Targeted Lung Cancer Treatment Causes Tumor Regression in Some Patients

Therapy Works Best in Never-Smokers

CHICAGO, June 1, 2003 – A new study suggests that a drug called erlotinib (TarcevaTM) has promising activity in patients with bronchioloalveolar cell carcinoma (BAC), a type of non-small cell lung cancer generally considered to be resistant to chemotherapy. Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) reported the preliminary results today at the American Society for Clinical Oncology annual meeting.

"While it is premature to make any conclusions about survival, we found that this treatment induced regressions that were often dramatic in patients with advanced BAC, and that the responses seem more durable and meaningful than what we have seen with chemotherapy," said the study's lead investigator Vincent Miller, MD, medical oncologist at MSKCC. "The treatment was especially effective in those patients who never smoked," he added.

Erlotinib is a small molecule that works by blocking the activity of an enzyme called "epidermal growth factor receptor (EGFR) tyrosine kinase," which helps communicate information within the cancer cell. EGFR is found on the surface of many tumor cells and may be involved in the growth and virulence of those cells.

BAC has certain pathologic and clinical features that distinguish it from other lung cancers. Approximately 3 percent of all lung cancer patients have what are called pure BAC tumors, but overall about 20 percent of an estimated 135,000 non-small cell lung cancers diagnosed each year possess some BAC features. BAC tends not to metastasize, but rather to spread within the lung causing symptoms such as shortness of breath and sputum production. Chemotherapy usually does not work as well for people with this type of lung cancer as it may in other types. BAC is increasing in incidence and it is more common in women and in individuals who never smoked. In this phase 2 study, 33 patients with BAC or adenocarcinomas with BAC features were accrued to the trial and began treatment between June and December of 2002. Nine of the patients never smoked. Eight out of 30 patients who completed at least one month of therapy achieved a partial response. Of the eight patients who responded, five never smoked, two smoked one pack a day for less than 10 years, and one was a heavy former smoker. Two patients died from progression of their disease.

"The particularly encouraging activity of this drug in never-smokers suggests that tobacco-related genetic changes in this patient population may influence resistance to this drug. Further research is necessary to address this possibility," said Dr. Miller.

According to the study's authors, BAC has not been well studied, yet it is a significant problem that needs to be looked at separately and perhaps treated differently in the future. Previous studies of erlotinib have shown promising activity in the treatment of advanced non-small cell lung cancer patients whose tumors had not responded to initial chemotherapy, and anecdotally, some of the most striking results occurred in individuals with BAC. This led investigators to conduct the current trial in an attempt to begin to better define the activity of this agent specifically in patients with BAC.

Patients in this study experienced modest side effects including rash and diarrhea, most of which seem to attenuate over time.

"This is not a panacea, but to see a therapy actually cause tumor regression in a meaningful percentage of patients with this disease is really unexpected and a pleasant surprise. The hope is to ultimately manage BAC like a chronic disease."

Investigators from Vanderbilt University Medical Center also contributed to the research, which was funded by Genentech Inc., South San Francisco, CA.

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.

Journalists may contact the Department of Public Affairs for more information.

Telephone: 212-639-3573

Email: publicaffairs@mskcc.org

http://www.mskcc.org/mskcc/html/13825.cfm

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.